Some third-generation EGFR-TKIs were designed to overcome drug resistance, among which osimertinib (TagrissoTM) was approved by the Food and Drug Administration (FDA) for the treatment of patients with NSCLC with EGFR L858R/T790M mutations [8,9,11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.